Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$26.62 USD
-0.23 (-0.86%)
Updated May 24, 2024 04:00 PM ET
After-Market: $26.99 +0.37 (1.39%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.62 USD
-0.23 (-0.86%)
Updated May 24, 2024 04:00 PM ET
After-Market: $26.99 +0.37 (1.39%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
What's in the Cards for Repros (RPRX) this Earnings Season?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Repros' Proellex Continues to be Under Partial Clinical Hold
by Zacks Equity Research
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
Repros to Meet with the FDA for Phase III Proellex Program
by Zacks Equity Research
Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.